Carcinoma, Transitional Cell Clinical Trial
Official title:
The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma
Cysteine-rich 61 (Cyr61), a member of "CCN" family, regulates cell migration, proliferation, apoptosis, and angiogenesis, cell adhesion, migration, proliferation, survival, differentiation, apoptosis, angiogenesis, and extracellular matrix production. Evidences show strong correlations of aberrant Cyr61 expression in cancers of numerous organs and tissues. However, the expression and effect of Cyr61 in transitional cell carcinoma (TCC), the most common urinary tract cancer in Taiwan, remains undiscovered. Based on previous studies of Cyr61 in other cancer, the investigators hypothesize that Cyr61 may mediate TCC cell proliferation and migration; and associated with disease progression and recurrent. Thus the investigators conduct this project to study the role of Cyr61 in the pathogenesis of TCC. The investigators will retrospectively review medical history of patients with TCC treated at our institutes. Cyr61 immunohistochemical stain of their surgical samples will be performed. The correlation of Cyr61 expression of TCC and patients' clinical courses will be investigated.
1. Patients: as shown in inclusion criteria
2. Surgical samples Surgical specimens from included patients with TCC who underwent
surgery will be collected. The samples will be examined histologically for the presence
of tumor cells. Independent pathologists who are blinded to the records of the patients
will perform histological examinations. Tumor grade is determined on the basis of
cytological features. There are three grades of TCC, as proposed by Mostofi et al. and
adopted by the American Bladder Tumor Registry of the World Health Organization. These
are based on degree of anaplasia: Grade 1 tumors show mild cytological atypia and rare
mitosis; Grade 2 tumors show moderate cytological atypical and the presence of mitotic
figures; and Grade 3 tumors show severe cytological atypia and frequent mitotic
figures. Lymph node metastasis, lymphatic invasion, and venous invasion will be
evaluated by pathology reports and image study. Clinical staging of TCC is based on the
American Joint Committee on Cancer staging (AJCC) TNM system.
3. Immunohistochemical stain Paraffin-embedded, formalin-fixed surgical specimens were
collected for Cyr61 immunohistochemical staining. Heat-induced epitope retrieval will
be performed with a pressure cooker and TRIS buffer (pH 9.0) for 2 min. They will be
allowed to cool for 15 min, rinsed in distilled water twice and in PBS for 5 min. The
sections will then be treated with 0.5% hydrogen peroxidase/PBS for 20 min at room
temperature to block the endogenous peroxidase. They will subsequently be blocked with
10% normal goat serum for 30 min at room temperature, and then incubated with
polyclonal anti-Cyr61 antibody (Santa Cruz, CA) at 4°C overnight. The specific
antibodies will be omitted in sections as negative controls. The sections will be
washed three times in PBS/0.2% Triton X-100 for 10 min and incubated with
biotin-conjugated secondary antibodies (DAKO, Carpinteria, CA) for 1 hour at room
temperature the following day. They will then be incubated with the
avidin-biotin-peroxidase reagent (DAKO) for another 1 hour at room temperature. After
three washes in PBS/0.2% Triton X-100 for 10 min each, the reactions on sections will
be detected with peroxidase substrate containing diaminobenzidine chromagen (DAKO). The
slides will be counterstained with hematoxylin. If >50% of the tumor cells are
positively stained, the specimen will be grouped as "positive". All other staining
results will be regarded as negative.
4. Statistical analysis For statistical analysis, P values are based on two-sided,
parametric Student's t tests. A P value of <0.05 on the basis of at least three
independent sets of experiments is considered to be statistically significant. In the
clinical sets of project, Chi-squire test and Student's t test will be used to study
the association of Cyr61 expression with single clinical factors (age, gender,
pathology, and grade). Kaplan-Meier survival curves for patients with positive versus
negative Cyr61 expression will be plotted and log-rank test will be used for comparing
the equality of the two survival curves. Cox proportional hazard model will also be
developed to correlate the clinical characteristics, survival, and the expression of
Cyr61.
;
Observational Model: Case-Only, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01215877 -
Tesetaxel for Previously Treated Patients With Bladder Cancer
|
Phase 2 | |
Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
Terminated |
NCT02450331 -
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
|
Phase 3 | |
Active, not recruiting |
NCT03288545 -
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00077688 -
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
|
Phase 2 | |
Recruiting |
NCT05874921 -
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
|
||
Completed |
NCT03410693 -
Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma
|
Phase 2/Phase 3 | |
Completed |
NCT02451423 -
Neoadjuvant Atezolizumab in Localized Bladder Cancer
|
Phase 2 | |
Completed |
NCT00001381 -
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
|
Phase 1 | |
Recruiting |
NCT05318339 -
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
|
Phase 2 | |
Completed |
NCT02443324 -
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
|
Phase 1 | |
Completed |
NCT00722553 -
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
|
Phase 2 | |
Recruiting |
NCT00146276 -
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
|
Phase 3 | |
Completed |
NCT02014337 -
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT00172367 -
Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
|
Phase 2 | |
Completed |
NCT00191971 -
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
|
Phase 2 | |
Terminated |
NCT00127595 -
Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract
|
Phase 2 | |
Terminated |
NCT04039867 -
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
|
Phase 2 | |
Completed |
NCT01529411 -
Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer
|
Phase 2 |